---
layout: default
title: Belimumab
description: "Belimumab çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 6 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 28
evidence_level: L5
indication_count: 6
---

# Belimumab

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>6</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Belimumabï¼šå¾ç´…æ–‘æ€§ç‹¼ç˜¡åˆ°è¡€å°æ¿åŠŸèƒ½éšœç¤™

## ä¸€å¥è©±ç¸½çµ
<p class="key-answer" data-question="Belimumab å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Belimumab æ˜¯æŠ— BLyS å–®æ ªæŠ—é«”ï¼Œç”¨æ–¼å…¨èº«æ€§ç´…æ–‘æ€§ç‹¼ç˜¡æ²»ç™‚ï¼ŒTxGNN é æ¸¬å…¶å¯èƒ½å°è¡€å°æ¿åŸç™¼æ€§é‡‹æ”¾éšœç¤™æœ‰æ•ˆã€‚
</p>


## å¿«é€Ÿç¸½è¦½
| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | å…¨èº«æ€§ç´…æ–‘æ€§ç‹¼ç˜¡ (SLE)ã€æ´»å‹•æ€§ç‹¼ç˜¡è…ç‚ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | primary release disorder of plateletsã€pseudo-von Willebrand diseaseã€Glanzmann thrombastheniaã€fetal and neonatal alloimmune thrombocytopeniaã€severe nonproliferative diabetic retinopathyã€autosomal dominant macrothrombocytopenia |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.96% |
| è­‰æ“šç­‰ç´š | L3 (é–“æ¥è‡¨åºŠè©¦é©—è­‰æ“š) |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 1 |
| å»ºè­°æ±ºç­– | Explore |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. primary release disorder of platelets</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.96%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

Belimumab é€éæŠ‘åˆ¶ B æ·‹å·´çƒåˆºæ¿€å› å­ (BLyS/BAFF) ä¾†èª¿ç¯€ B ç´°èƒåŠŸèƒ½ã€‚æ­¤é æ¸¬çš„ç”Ÿç‰©å­¸åˆç†æ€§åŸºæ–¼ï¼š
1. **è‡ªé«”å…ç–«æ©Ÿè½‰**ï¼šéƒ¨åˆ†è¡€å°æ¿åŠŸèƒ½éšœç¤™å¯èƒ½æ¶‰åŠè‡ªé«”æŠ—é«”ä»‹å°çš„è¡€å°æ¿æå‚·æˆ–åŠŸèƒ½æŠ‘åˆ¶
2. **å…ç–«æ€§è¡€å°æ¿æ¸›å°‘ç—‡é—œè¯**ï¼šSLE æ‚£è€…å¸¸è¦‹å…ç–«æ€§è¡€å°æ¿æ¸›å°‘ï¼Œbelimumab å¯èƒ½é€éæ¸›å°‘è‡ªé«”æŠ—é«”ç”¢ç”Ÿä¾†æ”¹å–„è¡€å°æ¿åŠŸèƒ½
3. **B ç´°èƒåœ¨è¡€å°æ¿ç”Ÿæˆä¸­çš„è§’è‰²**ï¼šB ç´°èƒå¯èƒ½é€éç´°èƒå› å­ç¶²çµ¡å½±éŸ¿è¡€å°æ¿ç”Ÿæˆå’ŒåŠŸèƒ½

ç„¶è€Œï¼Œã€Œè¡€å°æ¿åŸç™¼æ€§é‡‹æ”¾éšœç¤™ã€é€šå¸¸æ˜¯éºå‚³æ€§ç–¾ç—…ï¼Œbelimumab å°æ­¤é¡ç–¾ç—…çš„é©ç”¨æ€§å­˜ç–‘ã€‚

### è‡¨åºŠè©¦é©—

| è©¦é©—ç·¨è™Ÿ | éšæ®µ | ç‹€æ…‹ | æ”¶æ¡ˆäººæ•¸ | ä¸»è¦ç™¼ç¾ |
|----------|------|------|----------|----------|
| NCT01610492 | Phase 2 | å·²å®Œæˆ | 14 | ç‰¹ç™¼æ€§è†œæ€§è…ç—…è®Šç ”ç©¶ï¼Œæ¶‰åŠ PLA2R è‡ªé«”æŠ—é«”ï¼Œé–“æ¥èˆ‡è¡€å°æ¿åŠŸèƒ½ç›¸é—œ |

### ç›¸é—œæ–‡ç»

| PMID | å¹´ä»½ | æ¨™é¡Œ | ç›¸é—œæ€§ |
|------|------|------|--------|
| - | - | (ç„¡ç›´æ¥é‡å°è¡€å°æ¿é‡‹æ”¾éšœç¤™çš„æ–‡ç») | - |

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. pseudo-von Willebrand disease</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.96%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.96%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. Glanzmann thrombasthenia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.88%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.88%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. fetal and neonatal alloimmune thrombocytopenia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.59%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.59%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. severe nonproliferative diabetic retinopathy</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.05%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.05%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. autosomal dominant macrothrombocytopenia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.04%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.04%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š
| è¨±å¯è­‰è™Ÿ | ä¸­æ–‡å“å | åŠ‘å‹ | è¨±å¯è­‰æŒæœ‰è€… | æ•ˆæœŸ |
|----------|----------|------|--------------|------|
| è¡›ç½²èŒç–«è¼¸å­—ç¬¬000935è™Ÿ | å¥”éº—ç”Ÿå‡æ™¶æ³¨å°„åŠ‘ | å‡æ™¶æ³¨å°„åŠ‘ | è·å•†è‘›è˜­ç´ å²å…‹è—¥å»  | 2027/11/06 |

## å®‰å…¨æ€§è€ƒé‡
- **Major äº¤äº’ä½œç”¨ (é¿å…ä½µç”¨)**ï¼š
  - å…¶ä»–ç”Ÿç‰©è£½åŠ‘ï¼šadalimumab, etanercept, infliximab, certolizumab, golimumab
  - å…ç–«èª¿ç¯€åŠ‘ï¼šbaricitinib, leflunomide, teriflunomide, tofacitinib, fingolimod, natalizumab
  - æ´»ç–«è‹—ï¼šBCG, MMR, è¼ªç‹€ç—…æ¯’ç–«è‹—, é»ƒç†±ç—…ç–«è‹—ç­‰
  - å…¶ä»–ï¼šclozapine, cladribine
- **Moderate äº¤äº’ä½œç”¨**ï¼š
  - å¤šç¨®å…ç–«æŠ‘åˆ¶åŠ‘å’Œç–«è‹—
- 69 ç¨®å·²çŸ¥è—¥ç‰©äº¤äº’ä½œç”¨ï¼Œä½¿ç”¨æ™‚éœ€ä»”ç´°è©•ä¼°ä½µç”¨è—¥ç‰©


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Depressive Disorder** ğŸŸ¡ Moderate
- Psychiatric events have been reported with the use of belimumab.  Caution is recommended when prescribing this agent to patients with serious depression or suicidal behavior, history of depression, or other serious psychiatric disorders.  Patients re...

**Infections** ğŸŸ¢ Minor
- Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents.  Patients receiving immunosuppressants are at increased risk of developing bacterial, viral, fungal, and protozoal infections, and new or reacti...

**Leukoencephalopathy, Progressive Multifocal** ğŸŸ¢ Minor
- Immunosuppressive agents may increase the risk of progressive multifocal leukoencephalopathy (PML).  Certain agents are contraindicated in patients who have or have had PML.  Patients receiving chronic immunosuppressant or immunomodulatory therapy or...

## çµè«–èˆ‡ä¸‹ä¸€æ­¥
**æ±ºç­–ï¼šExplore**
**ç†ç”±ï¼š** é›–ç„¶ TxGNN é æ¸¬åˆ†æ•¸å¾ˆé«˜ï¼Œä½†è¡€å°æ¿åŸç™¼æ€§é‡‹æ”¾éšœç¤™å¤šç‚ºéºå‚³æ€§ç–¾ç—…ï¼Œbelimumab ä½œç‚º B ç´°èƒèª¿ç¯€åŠ‘çš„ä½œç”¨æ©Ÿè½‰èˆ‡æ­¤é¡ç–¾ç—…çš„ç—…ç†ç”Ÿç†å­¸é—œè¯ä¸æ˜ç¢ºã€‚å¯èƒ½çš„è§£é‡‹æ˜¯è©²é æ¸¬åæ˜ äº† belimumab å°è‡ªé«”å…ç–«ç›¸é—œè¡€å°æ¿åŠŸèƒ½éšœç¤™çš„æ½›åŠ›ã€‚
**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
1. é‡æ¸…é æ¸¬çš„å…·é«”ç–¾ç—…äºå‹ï¼šæ˜¯å¦æŒ‡è‡ªé«”å…ç–«æ€§è¡€å°æ¿åŠŸèƒ½éšœç¤™
2. å›é¡§ SLE è‡¨åºŠè©¦é©—ä¸­è¡€å°æ¿ç›¸é—œæŒ‡æ¨™çš„æ¬¡è¦åˆ†æ
3. è€ƒæ…®åœ¨å…ç–«æ€§è¡€å°æ¿æ¸›å°‘ç—‡ (ITP) æ—ç¾¤é€²è¡Œæ¢ç´¢æ€§ç ”ç©¶
4. è‹¥é‡å°éºå‚³æ€§è¡€å°æ¿é‡‹æ”¾éšœç¤™ï¼Œéœ€è¦æ›´å¤šåŸºç¤ç ”ç©¶æ”¯æŒ


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Tofacitinib]({{ "/drugs/tofacitinib/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Sulfamethazine]({{ "/drugs/sulfamethazine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Allopurinol]({{ "/drugs/allopurinol/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Aluminum Chloride]({{ "/drugs/aluminum_chloride/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Bevacizumab]({{ "/drugs/bevacizumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Belimumabè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/belimumab/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_belimumab,
  title = {Belimumabè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/belimumab/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
